Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.57 |
| ▸ | PPARA | Q07869 | 15/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4744011 | 1.00 | PPARG (0.57) | PPARGPPARACYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4748056 | 0.95 | PPARG (0.56) | PPARGPPARACYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4744028 | 0.95 | PPARG (0.56) | PPARGPPARACYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4744592 | 0.94 | PPARG (0.55) | PPARGPPARACYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4744029 | 0.94 | PPARG (0.55) | PPARGPPARACYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4744671 | 0.92 | PPARG (0.54) | PPARGPPARA | |
| SCHEMBL4744673 | 0.92 | PPARG (0.54) | PPARGPPARA | |
| SCHEMBL4747661 | 0.90 | PPARG (0.53) | PPARGPPARACYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4744313 | 0.90 | PPARG (0.53) | PPARGPPARACYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4744736 | 0.90 | PPARG (0.58) | PPARGPPARACYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008117982-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING LIPID ACCUMULATION CONTAINING SAME | CRYSTAL GENOMICS, INC. (KR) | 2008-10-02 | — | — | WO | disclosed |